Literature DB >> 2656781

A placebo-controlled, double-blind crossover study of naltrexone hydrochloride in outpatients with normal weight bulimia.

J E Mitchell1, G Christenson, J Jennings, M Huber, B Thomas, C Pomeroy, J Morley.   

Abstract

The endogenous opioid system plays an important role in the control of feeding behavior. Previous research has shown that antagonism of endogenous opioids will suppress feeding in certain models in both human and infrahuman species. In the current study, 16 normal-weight bulimic women were treated with low-dose naltrexone, the long-acting, orally active narcotic antagonist, and placebo in a crossover design. The use of the active drug was not associated with a clinically significant reduction in binge eating or vomiting episodes. Suggestions for further research in this area are offered.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2656781     DOI: 10.1097/00004714-198904000-00004

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

Review 1.  Appetite regulation: the role of peptides and hormones.

Authors:  J E Morley
Journal:  J Endocrinol Invest       Date:  1989-02       Impact factor: 4.256

Review 2.  Addicted to palatable foods: comparing the neurobiology of Bulimia Nervosa to that of drug addiction.

Authors:  Natalie A Hadad; Lori A Knackstedt
Journal:  Psychopharmacology (Berl)       Date:  2014-02-06       Impact factor: 4.530

Review 3.  Hormonal and neural mechanisms of food reward, eating behaviour and obesity.

Authors:  Susan Murray; Alastair Tulloch; Mark S Gold; Nicole M Avena
Journal:  Nat Rev Endocrinol       Date:  2014-06-24       Impact factor: 43.330

4.  Pharmacotherapies for Overeating and Obesity.

Authors:  S Yarnell; M Oscar-Berman; Nm Avena; K Blum; Ms Gold
Journal:  J Genet Syndr Gene Ther       Date:  2013-04-01

Review 5.  Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa.

Authors:  Susan L McElroy; Anna I Guerdjikova; Nicole Mori; Francisco Romo-Nava
Journal:  CNS Drugs       Date:  2019-01       Impact factor: 5.749

Review 6.  Current perspectives on drug therapies for anorexia nervosa and bulimia nervosa.

Authors:  S H Kennedy; D S Goldbloom
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 7.  Eating disorders in children and adolescents: pharmacological therapies.

Authors:  L A Kotler; B T Walsh
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

8.  Naltrexone Reduces Binge Eating and Purging in Adolescents in an Eating Disorder Program.

Authors:  Stephani L Stancil; William Adelman; Amanda Dietz; Susan Abdel-Rahman
Journal:  J Child Adolesc Psychopharmacol       Date:  2019-07-16       Impact factor: 2.576

9.  Naltrexone in primary hyperphagic obesity wity hypochondriacal disorder - a clinical study.

Authors:  R S Pandey; S C Arya; D K Subbakrishna
Journal:  Indian J Psychiatry       Date:  1999-04       Impact factor: 1.759

Review 10.  Cognitive-behavioural therapy for individuals with bulimia nervosa and a co-occurring substance use disorder.

Authors:  Robyn Sysko; Tom Hildebrandt
Journal:  Eur Eat Disord Rev       Date:  2009-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.